Bulimia Nervosa Clinical Trial
Official title:
Dopamine Release to Food Reward in Bulimia Nervosa: an [18F]-Fallypride PET/MR Study.
This study will assess the role of dopamine responses to food reward in Bulimia Nervosa patients, by performing simultaneous Positron Emission Tomography (PET) and Magnetic Resonance (MR) scanning. The dopamine response will be measured before and after treatment, and will be compared to healthy controls.
Bulimia nervosa is a psychiatric eating disorder characterized by recurrent episodes of binge
eating, followed by inappropriate compensatory behaviour. It is associated with a high
disease burden and high rates of medical and psychiatric comorbidities. Only 50% of patients
achieve long-term remission, indicating the need for a better understanding of the
pathophysiology which can guide the development of new treatment options.
There are strong indications for an involvement of the brain's dopaminergic reward system in
Bulimia Nervosa, such as the presence of elevated craving for rewarding food and poorer
impulse control. However, there is no clear evidence on the exact involvement of the reward
system nor direct evidence of abnormal dopamine responses to food reward. Therefore, the
current study will assess dopamine release and related brain activity to food reward in
Bulimia Nervosa patients, by performing simultaneous Positron Emission Tomography (PET) and
Magnetic Resonance (MR) scanning. Specifically, the investigators will compare dopamine
release in Bulimia Nervosa patients to healthy controls, and assess the effect of successful
treatment on the food reward response. To this end, 20 Bulimia Nervosa patients will
participate in one PET-MR scan before the start of inpatient treatment and in a second PET-MR
scan at the end of inpatient treatment. Additionally, PET-MR scans will be obtained from a
group of 20 healthy control participants.
All scan session will measure dopamine release to a combination of anticipatory (viewing
high-calorie food images) and consummatory (drinking sips of chocolate milkshake) food reward
and will be conducted in a fasted state. The scan sessions will consist of four blocks with a
duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent
the 'control condition' and the fourth block the 'food reward condition'. During both
sessions, blood samples will be collected at several time points to assess levels of
metabolic hormones and their relation to food-induced dopamine release.
This study aims to improve our understanding of the disease process underlying Bulimia
Nervosa and to enable the identification of new and specific treatment targets at multiple
levels of the gut-brain axis, including the dopamine system in the brain but also metabolic
hormones and the interactions between both. Additionally, the results may have the potential
to guide the optimisation of behavioural treatment approaches with a stronger focus on
aberrant reward system responses.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Withdrawn |
NCT00988481 -
Topiramate Augmentation in Bulimia Nervosa Partial Responders
|
Phase 4 | |
Completed |
NCT00184301 -
A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.
|
N/A | |
Completed |
NCT00522769 -
Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Recruiting |
NCT04409457 -
Self-Control in Bulimia Nervosa
|
N/A | |
Recruiting |
NCT05509257 -
Naltrexone Neuroimaging in Teens With Eating Disorders
|
Early Phase 1 | |
Recruiting |
NCT05937243 -
Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating
|
N/A | |
Recruiting |
NCT05862389 -
Study on the Mechanism of Eating Disorder
|
||
Recruiting |
NCT05728021 -
Smartphone-based Aftercare for Inpatients With Bulimia Nervosa
|
N/A | |
Completed |
NCT03781921 -
The Neural Bases of Emotion Regulation in Bulimia Nervosa
|
||
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Terminated |
NCT04041024 -
Decision-making and Risk-taking in Bulimia
|
N/A | |
Completed |
NCT04265131 -
Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?
|
N/A | |
Recruiting |
NCT06431854 -
Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program
|
N/A | |
Recruiting |
NCT02960152 -
Periodontal Impact of Eating Disorders (the PERIOED Study)
|
N/A | |
Completed |
NCT00916071 -
Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
|
N/A | |
Terminated |
NCT00308776 -
Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa
|
N/A |